ATS 2024 Final Program

Click on the session title to view the speakers

SUNDAY • MAY 19

79

P417 The Effect of Body Mass Index on Ventilatory Parameters During Cardiopulmonary Exercise Testing P418 Ventilatory Constraints in Patients With HFpEF During Exercise: Impact of Lung Size and Upper Body Adiposity

P429 Treprostinil Inhibits Human Lung Fibroblast Matrix Production Via the IP Receptor Independently of cAMP P430 TRIM36 Degrades Phosphorylated AKT to Suppress Pulmonary Fibrosis P431 The Effect of Adrenalectomy on Bleomycin-induced Pulmonary Fibrosis in Mice Model P432 Specific Modified mRNA Translation System (SMRTS) for the Attenuation of Pulmonary Fibrosis P433 Galectin-3 Promotes Fibroblast-myofibroblast Differentiation Inidiopathic Pulmonary Fibrosis P434 Targeting Gremlin2 Is a Promising Approach for Treating Pulmonary Fibrosis P435 A Novel Target for Idiopathic Pulmonary Fibrosis, A Kinase Anchoring Protein 13 (AKAP13), Is Required for TGF-ß-Induced Extracellular Matrix Production by Promoting the Phosphorylation of CREB-1 and Increasing SMAD-3 Levels P436 Identification of Characteristic Pathways and Groups of Marker Molecules in IPF With Machine Learning Using Cryobiopsy RNASeq Data P437 Assessing Challenges and Opportunities for Biomarker, Device, and Pre-clinical Drug Development/Commercialization in the Pulmonary Arena P438 The Effect of Nintedanib on the cav2-null Mouse Model of Pulmonary Fibrosis P439 Post-hoc Analysis of Biomarkers of Interstitial Lung Disease Progression in Participants With Idiopathic Pulmonary Fibrosis Receiving Bexotegrast Over 12-weeks in INTEGRIS-IPF P440 Anti-WISP1 (MTX-463) as a Novel Potential Therapy for Idiopathic Pulmonary Fibrosis P441 Targeted Therapeutic Disruption of the Focal Adhesion Scaffold Inhibits Bleomycin Induced Fibrosis

BASIC • TRANSLATIONAL THEMATIC POSTER SESSION

A68 UNVEILING NOVEL AVENUES IN IPF THERAPIES 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P420 Analysis of Local Distribution and Residence Time of Nintedanib in Fibrotic Lung Tissue Using Mass Spectrometry Imaging P421 Anti-Fibrotic Agent, Drug #765, Ameliorates Fibrosis by Inhibiting Lysyl Oxidase Like-2 Activity P422 Apelin-APJ Signaling Is Reduced in IPF Lungs and Attenuates TGF-ß1-induced Lung Fibrosis P423 Tryptophan Metabolite Indole-3-acetic Acid Ameliorates Pulmonary Fibrosis by Regulating Lung Microbiota and Inducing Autophagy Via Inhibition of the PI3K/AKT/MTOR Pathway P424 Targeting the Extracellular Cyclic AMP Pathway in Idiopathic Pulmonary Fibrosis P425 Attenuation of Pulmonary Fibrosis by Targeting IL-33 Precursor Protein With Cell-permeable Decoy Peptides in the Bleomycin Model P426 Ex-vivo Evaluation of the Potential for Narrow Spectrum Kinase Inhibitors as a Treatment for Idiopathic Pulmonary Fibrosis P427 The Effect of Novel Autotaxin Inhibitor, 2-carba Cyclic Phosphatidic Acid, in Lung Fibrosis P428 Melatonin Ameliorates Bleomycin-induced Pulmonary Fibrosis by Down-regulating Galectin-3 Expression San Diego Convention Center Area E (Hall A-B2, Ground Level)

ATS 2024 Conference Program • San Diego, CA